These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 8510938

  • 1. The proteins encoded by c-akt and v-akt differ in post-translational modification, subcellular localization and oncogenic potential.
    Ahmed NN, Franke TF, Bellacosa A, Datta K, Gonzalez-Portal ME, Taguchi T, Testa JR, Tsichlis PN.
    Oncogene; 1993 Jul; 8(7):1957-63. PubMed ID: 8510938
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Transforming activity of the RL-akt gene, a c-akt gene activated by long terminal repeat insertion in murine leukemia RL(male symbol)1 cells.
    Tanino M, Matsuo M, Uenaka A, Tsukuda K, Ouchida M, Nakayama E, Shimizu K.
    Mol Carcinog; 1999 Dec; 26(4):286-97. PubMed ID: 10569805
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
    Mosialos G, Gilmore TD.
    Oncogene; 1993 Mar; 8(3):721-30. PubMed ID: 8437855
    [Abstract] [Full Text] [Related]

  • 6. Carboxyl-terminal modulator protein (CTMP), a negative regulator of PKB/Akt and v-Akt at the plasma membrane.
    Maira SM, Galetic I, Brazil DP, Kaech S, Ingley E, Thelen M, Hemmings BA.
    Science; 2001 Oct 12; 294(5541):374-80. PubMed ID: 11598301
    [Abstract] [Full Text] [Related]

  • 7. The product of the cellular crk gene consists primarily of SH2 and SH3 regions.
    Reichman CT, Mayer BJ, Keshav S, Hanafusa H.
    Cell Growth Differ; 1992 Jul 12; 3(7):451-60. PubMed ID: 1329926
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. v-myc and v-raf act synergistically to induce B-cell tumors in pristane-primed adult BALBC mice.
    Kurie JM, Morse HC, Principato MA, Wax JS, Troppmair J, Rapp UR, Potter M, Mushinski JF.
    Oncogene; 1990 Apr 12; 5(4):577-82. PubMed ID: 2183159
    [Abstract] [Full Text] [Related]

  • 10. Six amino acids from the retroviral gene gag greatly enhance the transforming potential of the oncogene v-erb-B.
    Bruskin A, Jackson J, Bishop JM, McCarley DJ, Schatzman RC.
    Oncogene; 1990 Jan 12; 5(1):15-24. PubMed ID: 1969616
    [Abstract] [Full Text] [Related]

  • 11. Rejection antigen peptides on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes: derivation from the normally untranslated 5' region of the c-akt proto-oncogene activated by long terminal repeat.
    Wada H, Matsuo M, Uenaka A, Shimbara N, Shimizu K, Nakayama E.
    Cancer Res; 1995 Nov 01; 55(21):4780-3. PubMed ID: 7585504
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma.
    Staal SP.
    Proc Natl Acad Sci U S A; 1987 Jul 01; 84(14):5034-7. PubMed ID: 3037531
    [Abstract] [Full Text] [Related]

  • 14. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region.
    Bellacosa A, Testa JR, Staal SP, Tsichlis PN.
    Science; 1991 Oct 11; 254(5029):274-7. PubMed ID: 1833819
    [Abstract] [Full Text] [Related]

  • 15. Mutational analysis of v-rel, the oncogene of reticuloendotheliosis virus strain T.
    Bhat GV, Temin HM.
    Oncogene; 1990 May 11; 5(5):625-34. PubMed ID: 2189101
    [Abstract] [Full Text] [Related]

  • 16. Differences in kappaB DNA-binding properties of v-Rel and c-Rel are the result of oncogenic mutations in three distinct functional regions of the Rel protein.
    Nehyba J, Hrdlicková R, Bose HR.
    Oncogene; 1997 Jun 19; 14(24):2881-97. PubMed ID: 9205096
    [Abstract] [Full Text] [Related]

  • 17. A new mechanism of oncogenic activation: E26 retroviral v-ets oncogene has inverted the C-terminal end of the transcription factor c-ets-1.
    Leprince D, Crepieux P, Laudet V, Flourens A, Stehelin D.
    Virology; 1993 Jun 19; 194(2):855-7. PubMed ID: 8389086
    [Abstract] [Full Text] [Related]

  • 18. Tyrosine protein kinase activity of the HZ4-feline sarcoma virus P80gag-kit-transforming protein.
    Majumder S, Ray P, Besmer P.
    Oncogene Res; 1990 Jun 19; 5(4):329-35. PubMed ID: 1697669
    [Abstract] [Full Text] [Related]

  • 19. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
    Okazaki M, Kishida S, Murai H, Hinoi T, Kikuchi A.
    Cancer Res; 1996 May 15; 56(10):2387-92. PubMed ID: 8625316
    [Abstract] [Full Text] [Related]

  • 20. Expression of the human dbl-oncogene and proto-oncogene products in insect cells using a baculovirus vector.
    Graziani G, Ron D, Srivastava S, Eva A.
    Ann Ist Super Sanita; 1991 May 15; 27(1):115-21. PubMed ID: 1958019
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.